Leridistim - Pharmacia Corporation

Alternative Names: Myelopoietin; SC 68420; Stem cell factor - Pharmacia

Latest Information Update: 23 Sep 2021

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Pharmacia Corporation
Class Antineoplastics; Colony-stimulating factors; Interleukins; Recombinant fusion proteins
Mechanism of Action Granulocyte colony-stimulating factor receptor agonists; Interleukin 3 receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

31 Jul 2000 Discontinued-III for Stem cell mobilisation in USA (SC)
05 Apr 2000 Monsanto has merged with Pharmacia & Upjohn to form Pharmacia Corporation
20 Jan 2000 Yamanouchi has exercised its option to develop and market leridistim in Japan

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com